12 results about "Forced swimming" patented technology

This invention belongs to the field of swimming land-based training equipment, specifically a V-force swimming land-based training equipment with water-catching and water-pushing functions. It includes: a bottom frame for support, on which a support component for the athlete to lie prone is mounted; a mounting shell, fixedly mounted on the top of the bottom frame, containing a motor connected to a left and right drum; photoelectric devices mounted on the motor's output shaft, the left drum, and the right drum; the photoelectric devices include a code disk and a slotted optocoupler; two pull ropes, respectively mounted on the left and right drums, each with a fixed mounting rod at one end, and a handle fixedly mounted at one end of each rod; and a pulley assembly, mounted on the top of the bottom frame, for guiding the two pull ropes. This invention solves the problem of "unresponsive start-up and loss of responsiveness during deceleration" in traditional isokinetic training equipment, accurately simulating the instantaneous support sensation of catching water and the continuous resistance sensation of pushing water.

The application belongs to the technical field of biomedicine, and particularly relates to a benzene sulfonamide derivative and application thereof in antidepressant drugs. The structural general formula of the compound is (I). The compound or a pharmaceutically acceptable salt thereof has agonistic activity on 5-hydroxytryptamine 2A type receptors. The compound is determined to have good antidepressant activity through a mouse tail suspension test model, an open field test model and a forced swimming test model, is a novel antidepressant compound with wide application prospect, has no hallucinogenic effect, and can be developed into an antidepressant therapeutic drug.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of a Dan'e Fukang preparation in preparation of a medicine for treating perimenopausal syndrome. The invention provides application of a Dan'e Fukang preparation in preparation of a medicine for treating perimenopausal syndrome. Pharmacological experiments prove that Dan'e Fukang can reduce the number of activities of mice and prolong the sleep time of the barbital sodium of the mice, and has certain sedative, hypnotic and anxiety-resistant effects; the composition can effectively resist rat foot plantar sweat secretion caused by pilocarpine, and has a certain effect of resisting sweating; moreover, the traditional Chinese medicine composition has an obvious effect of reducing LH, FSH and T in climacteric rats, has an effect of increasing E2 in serum of the climacteric rats, and can be used for effectively treating the perimenopausal syndrome. Dan'e'fukang can reduce the total accumulated immobility time of the rat in the forced swimming experiment; the despair state time of a tail suspension experiment rat is obviously shortened, and a certain anti-depression effect is achieved. The Dan'e Fukang can provide more drug choices for clinical treatment of perimenopausal syndrome diseases.

The invention belongs to the technical field of medicine preparation, discloses a preparation method of a composite microbial preparation, focuses on a specific co-disease group of'depression-constipation-sleep disorder 'for the first time, provides a single-preparation comprehensive solution for comprehensively adjusting'intestine-brain axis' through multi-strain synergy, and fills the market blank. Constipation indexes are as follows: the intestinal tract propulsion rate of mice is increased by 50%, and the discharge time of first black feces is shortened by 30%. The depression index is as follows: in a forced swimming experiment, the immobile time is reduced by 40%, and the sweet water preference is obviously increased. Sleep indexes are as follows: the total sleep time is prolonged by 25%, and the sleep latency period is shortened by 20%. Biochemical indexes are as follows: the level of inflammatory factor IL-6 in serum is reduced by 60%, and the content of 5-HT and GABA in colon tissue is remarkably increased.

The invention provides application of Turicibacter sanguinis in preparation of a medicine for preventing and / or treating depression, and belongs to the technical field of biological medicine. Researches find that compared with depression model mice, mice treated by T. sanguinis show significant behavior improvement: sucrose consumption is increased, retention time in an interaction area in a social interaction experiment (a CD1 mouse introduction stage) is prolonged, retention time and total movement distance in a central area in an open field experiment are both increased, and the mice treated by T. sanguinis show significant behavior improvement. And meanwhile, the standing time in a forced swimming experiment is shortened. The results of the behavioral test are consistent to show that the depression-like behavior of the mouse can be obviously alleviated by the T. sanguinis intervention.

The application discloses an experimental device and method for rodent forced swimming and swimming training intervention, and belongs to the technical field of animal experiment devices, which comprises a swimming container, the swimming container is divided into multiple animal swimming cabins through multiple cabin inter-plate, the cabin inter-plate can be lifted, when being lifted higher than the highest experimental water level, the multiple animal swimming cabins are independent, when being lowered to the cabin bottom plate, the multiple animal swimming cabins are communicated, each animal swimming cabin is provided with a lifting platform and a laser radar system, the lifting platform is provided with a weighing structure, the weighing structure detects the mass signal of experimental animals, the laser radar system detects the water surface fluctuation signal in the cabin, and the application further comprises a main control system, which is in communication connection with the swimming container. The application can simultaneously realize forced swimming experiment and swimming training intervention experiment, improves the applicability of the device, and accurately judges the state of the rodent in the experiment process, so that the experimental animal is prevented from being drowned.

The application discloses application of hippuric acid in preparation of a medicine for preventing and / or treating depression, and belongs to the technical field of biological medicine. The hippuric acid or pharmaceutically acceptable salt thereof has significant and multi-target antidepressant pharmacological activity through chronic mild stress depression animal model experiment. Specifically, in terms of improving core depressive symptoms, the sugar water preference experiment result shows that the hippuric acid can effectively reverse CUMS-induced hedonic deficiency of mice, and significantly improves the sucrose preference rate, and the forced swimming experiment proves that the hippuric acid can significantly shorten the immobility time of mice and relieve behavioral despair; in terms of improving anxiety-like behavior, the mine field experiment data show that after the hippuric acid intervention, the number of times of entering the central area, the residence time and the total activity distance of the depressive model mice are all significantly increased, which indicates that the hippuric acid can effectively improve the spontaneous activity reduction caused by chronic stress.

The invention discloses an application of polypeptide in preparation of antidepressant drugs, and belongs to the field of biological medicine, the polypeptide is neuropeptide PEN or a functional fragment and a derivative thereof, and the PEN is one of a plurality of derivative peptides formed by cutting a protein precursor proSAAS existing in a central nervous system of a mammal through proprotein convertase. Research finds that PEN as an endogenous polypeptide can significantly shorten the immobility time of a mouse in a tail suspension experiment and a forced swimming experiment and improve the depression-like behavior of the mouse, shows an obvious anti-depression effect, and has no obvious influence on the movement function of the mouse. A further research result shows that the anti-depression mechanism of PEN is related to inhibition of NMDAR2B / CaMKII signals of a mouse hippocampus and increase of ERK1 / 2 protein activity of the hippocampus. The invention discovers potential application of PEN in preparation of antidepressant drugs for the first time, and provides a new target and theoretical basis for development of novel, safe and effective antidepressant drugs.

Provided in the present invention is a novel use of Pynegabine as represented by formula (I) in the preparation of drugs for treating or preventing psychiatric disorders such as depression and schizophrenia. The present invention shows that Pynegabine can exhibit a significant antidepressant effect in an acute forced swimming mouse model and a chronic social defeat stress mouse model; additionally, Pynegabine also has a significant alleviation effect on both positive and negative symptoms in an MK-801-induced mouse model of schizophrenia. The present invention shows good development and application prospects.

The invention discloses an application of a medicine for relieving senile depression and a verification method of the medicine, and relates to a new application of Ro61-8048 in preparation of the medicine for relieving the senile depression, and provides a verification method based on a chronic unpredictable mild stress (CUMS) model of a 18-month-old C57BL / 6J mouse. Six behavioral indexes of sucrose preference, open field, new object recognition, Y maze, forced swimming and social interaction prove that by intraperitoneal administration of 50 mg / kg Ro61-8048, low emotion, anxiety level rise and cognitive impairment of an old depression model mouse can be remarkably reversed, the curative effect is equivalent to that of a classic antidepressant fluoxetine hydrochloride (20 mg / kg), and no obvious side effect is caused to normal old mice. The invention provides an experimental basis and a drug effect evaluation platform for taking the KMO inhibitor as a novel treatment strategy of the LLD.

The invention belongs to the technical field of medicines, and provides application of urolithin A acetate and a derivative thereof in preparation of a medicine for treating depression and the prepared antidepressant medicine. The application dosage is 0.01-30 mg / kg of urolithin A acetate or a derivative thereof, and the anti-depression effect can be generated within 60 minutes after administration. After the medicine is administrated for 5 days, the obvious anti-depression effect is generated in the low dosage and the high dosage. A research result shows that in a mammal mouse tail suspension experiment, the urolithin A acetate or the derivative thereof has a rapid anti-depression effect and is more effective than an anti-depression drug imipramine. According to the method, a forced swimming experiment and a mouse tail suspension experiment are adopted as drug screening experiments, and meanwhile, an open field test is carried out on the mouse, so that the autonomous activity of the mouse is detected, and interference of central excitants is avoided. The anti-depression drug has the advantages of being remarkable in anti-depression effect, quick in effect taking, small in dosage, small in side effect and the like, and is expected to become a new anti-depression drug which is quick, efficient and novel in mechanism.

The present application provides a new use of pirenzepine in the preparation of a drug for treating or preventing mental diseases such as depression and schizophrenia. The present application shows that pirenzepine can exhibit a significant antidepressant effect in a mouse acute forced swimming model and a chronic social defeat stress model, and can significantly alleviate the positive and negative symptoms of an MK-801 induced schizophrenia mouse model. It has a good development and application prospect.